The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.
Exosomes from mesenchymal stem cells can increase hair growth by enhancing anagen duration and hair shaft thickness through the Wnt/beta-catenin pathway. Phase 2 trials show improved hair counts over 24 weeks.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
A user has been taking finasteride for 7 months and is experiencing watery semen as the only side effect. They are considering taking zinc supplements to improve this condition.
OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.
A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.
Long-term use of dutasteride may impair semen volume and sperm motility, but these effects are often reversible after stopping the drug. Individual reactions vary, and more research is needed to understand the long-term impact on fertility.
The user has been using finasteride for 3 years with good results and wants to switch to dutasteride combined with tamsulosin. They are seeking more information about tamsulosin.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
Finasteride and dutasteride are not considered safe during pregnancy, with some users suggesting caution and others sharing personal experiences of no issues. The general consensus is to avoid these medications during pregnancy to prevent any potential risks.
Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.
The user has been using dutasteride and oral minoxidil for 60 days, noticing thin baby hairs on their temples. They are anxious about progress and plan to update after 90 days, while others advise patience.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The user reports improved crown hair regrowth after 5 months of using Dutasteride and Minoxidil, but minimal change in the front/temples. Others suggest waiting 12-18 months for full results and note that temple regrowth is typically slower.
Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for alopecia treatment. They enhance cell viability, maintain stemness, and induce hair growth without teratoma formation.
Fibrin-based hydrogels support stem cells for hair follicle regeneration, showing promise for treating alopecia and wound healing. They enhance cell viability, maintain stemness, and promote hair and tissue regeneration without teratoma formation.
The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
Dutasteride in semen is considered a very small risk for partners, and fertility typically improves after stopping the medication. It is recommended to stop Dutasteride 3-6 months before trying to conceive to avoid potential impacts on fertility and fetal development.
Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
Apple core extract pills, believed to enhance hair density, are discussed as a potential treatment for hair loss. Users express cautious optimism and interest in trying the product, while acknowledging skepticism and the high cost.